Key result
Premature atherosclerosis in SLE may be driven by inflammation- or steroid-induced dyslipoproteinemia requiring lipid-lowering therapy.
Highlights the need for early screening and potential pharmacological management of dyslipoproteinemia to prevent premature atherosclerosis in patients with systemic lupus erythematosus.
No takes yet. Share an insight, caveat, or question.
Supports early dyslipidemia screening in SLE; leaves open whether lipid-lowering therapy prevents premature atherosclerosis.
Norman T. Ilowite (1996) conducted a review in Systemic lupus erythematosus and rheumatic diseases. Premature atherosclerosis in systemic lupus erythematosus may be driven by dyslipoproteinemia from chronic inflammation or corticosteroid therapy, sometimes requiring lipid-lowering drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: